Rani Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.62 Mil. Rani Therapeutics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $24.48 Mil. Rani Therapeutics Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $12.87 Mil.
Rani Therapeutics Holdings's debt to equity for the quarter that ended in Dec. 2023 was 2.34.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Rani Therapeutics Holdings's Debt-to-Equity or its related term are showing as below:
RANI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: 0.82 Max: 2.34
Current: 2.34
During the past 5 years, the highest Debt-to-Equity Ratio of Rani Therapeutics Holdings was 2.34. The lowest was -0.03. And the median was 0.82.
Rani Therapeutics Holdings Debt-to-Equity Historical Data
The historical data trend for Rani Therapeutics Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Rani Therapeutics Holdings Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
- |
-0.03 |
- |
0.82 |
2.34 |
|
Rani Therapeutics Holdings Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
0.82 |
1.00 |
1.26 |
1.73 |
2.34 |
Competitive Comparison
For the Biotechnology subindustry, Rani Therapeutics Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rani Therapeutics Holdings Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Rani Therapeutics Holdings's Debt-to-Equity falls into.
Rani Therapeutics Holdings Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Rani Therapeutics Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Rani Therapeutics Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rani Therapeutics Holdings (Rani Therapeutics Holdings) Business Description
Traded in Other Exchanges
N/A
Address
2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
Executives
| Talat Imran |
director, officer: CEO |
C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131 |
| South Cone Investments Limited Partnership |
10 percent owner |
AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000 |
| Quiroga Cortes Isidoro Alfonso |
10 percent owner |
9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759 |
| Jean Luc Butel |
director |
ONE BAXTER PARKWAY, DEERFIELD IL 60015 |
| Maulik Nanavaty |
director |
BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
| Kate Mckinley |
officer: CHIEF BUSINESS OFFICER |
C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131 |
| Svai S Sanford |
officer: CFO |
C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131 |
| Eric Groen |
officer: General Counsel |
C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131 |
| Mir Hashim |
officer: Chief Scientific Officer |
C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131 |
| South Lake One Llc |
10 percent owner |
250 WEST 55TH STREET, NEW YORK NY 10019 |
| Aequanimitas Limited Partnership |
10 percent owner |
LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500 |
| Mir A Imran |
director |
|
| Andrew Farquharson |
director |
C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131 |
| Laureen Debuono |
director |
|
| Lisa Ann Rometty |
director |
C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131 |
Rani Therapeutics Holdings (Rani Therapeutics Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RANI has been successfully added to your